This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

The protein NOS2 isn't good for ER-negative breast cancer patients

October 18th, 2010

Breast cancers can be divided into different subtypes based on several criteria, including whether or not they express the protein to which the female hormone estrogen binds; that is, the estrogen receptor (ER). Patients with ER-negative breast tumors have a worse outlook than those with ER-positive breast tumors. However, even among ER-negative breast tumors, those characterized as basal-like are the most aggressive and difficult to treat. New therapeutic targets for this subtype of breast cancer are urgently needed. Now, a team of researchers, led by Stefan Ambs, at the National Cancer Institute, Bethesda, report data that suggest that the protein NOS2 could be a good drug target in this context. The data, generated by analysis of human breast cancer samples and cell lines, lead the authors to conclude that high levels of NOS2 are a predictor of survival in patients with ER-negative breast tumors and to suggest that selective NOS2 inhibitors might be of benefit to these individuals.

More information:
View this article at: www.jci.org/articles/view/4205 … e19810fc296c1ecf1474

Provided by Journal of Clinical Investigation

Citation: The protein NOS2 isn't good for ER-negative breast cancer patients (2010, October 18) retrieved 16 August 2026 from https://sciencex.com/wire-news/48859868/the-protein-nos2-isnt-good-for-er-negative-breast-cancer-patient.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.